| International Session（Symposium）2(JSGE・JGES) |
| Thu. November 21st 14:00 - 16:30 Room 11: Portopia Hotel South Wing Topaz |
| Investigations of the characteristics and efficacy of anti-TNFα agents for optimizing treatment in pediatric patients with new-onset Crohn’s disease | |||
| Yoko Yokoyama1, Kenji Watanabe1, Shiro Nakamura2 | |||
| 1Department of Intestinal Inflammation Research, Hyogo College of Medicine, 2Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo College of Medicine | |||
|
|||
|
|||
| Background We investigated the characteristics of pediatric Crohn’s disease (CD) patients and the efficacy of anti-TNFα agents o illustrate real-world data. Methods In this single center retrospective case-control study, we investigated 236 CD patients newly diagnosed at our hospital. We compared the characteristics and efficacies of anti-TNFα agents between the pediatric group (≦17 years) and the non-pediatric group. Results The pediatric group accounted for 22.9%. The complications of extraintestinal manifestations and inflammatory type of behavior were significantly more common in the pediatric group (40.7 vs 7.1%; 90.7 vs 59.9%). The rates of clinical remission and mucosal healing within a year were not different between the two group (90.6 vs 84.2%; 77.8 vs 76.9%). The cumulative LOR rate in the primary responders was not different between the two groups (13.8 vs 17.5% at one year and 37.9% vs 35.0% at 5 years: P=0.76). Significantly lower hemoglobin, higher C-reactive protein and PCDAI at baseline were observed in the pediatric LOR group than in the pediatric remission maintenance group (P<0.05). Conclusion The inflammatory type and the extraintestinal manifestations were frequent. The introduction of anti-TNFα agents as combination therapy with immunomodulators should be considered to avoid LOR in high-risk pediatric CD patients. |
|||
|
Index Term 1: pediatric crohn’s disease patients Index Term 2: anti-TNFα agents |
|||
| Page Top | |||